MX2020010458A - Conjugados de camptotecina-peptido. - Google Patents

Conjugados de camptotecina-peptido.

Info

Publication number
MX2020010458A
MX2020010458A MX2020010458A MX2020010458A MX2020010458A MX 2020010458 A MX2020010458 A MX 2020010458A MX 2020010458 A MX2020010458 A MX 2020010458A MX 2020010458 A MX2020010458 A MX 2020010458A MX 2020010458 A MX2020010458 A MX 2020010458A
Authority
MX
Mexico
Prior art keywords
camptothecin
peptide conjugates
camptothecin peptide
conjugates
compounds
Prior art date
Application number
MX2020010458A
Other languages
English (en)
Spanish (es)
Inventor
Scott Jeffrey
Maureen Ryan
Ryan Lyski
Julia Cochran
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2020010458A publication Critical patent/MX2020010458A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
MX2020010458A 2018-04-06 2019-04-05 Conjugados de camptotecina-peptido. MX2020010458A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653961P 2018-04-06 2018-04-06
PCT/US2019/025968 WO2019195665A1 (en) 2018-04-06 2019-04-05 Camptothecin peptide conjugates

Publications (1)

Publication Number Publication Date
MX2020010458A true MX2020010458A (es) 2021-01-29

Family

ID=68101237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010458A MX2020010458A (es) 2018-04-06 2019-04-05 Conjugados de camptotecina-peptido.

Country Status (16)

Country Link
US (3) US20190343828A1 (cg-RX-API-DMAC7.html)
EP (1) EP3773736A4 (cg-RX-API-DMAC7.html)
JP (2) JP7430643B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210006362A (cg-RX-API-DMAC7.html)
CN (1) CN111936169A (cg-RX-API-DMAC7.html)
AR (1) AR114473A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019247434A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020466A2 (cg-RX-API-DMAC7.html)
CA (1) CA3094313A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092410A1 (cg-RX-API-DMAC7.html)
IL (2) IL310391A (cg-RX-API-DMAC7.html)
MA (1) MA52669A (cg-RX-API-DMAC7.html)
MX (1) MX2020010458A (cg-RX-API-DMAC7.html)
SG (1) SG11202009527PA (cg-RX-API-DMAC7.html)
TW (1) TW202010498A (cg-RX-API-DMAC7.html)
WO (1) WO2019195665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
RS64961B1 (sr) * 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
JP7880815B2 (ja) * 2019-10-01 2026-06-26 メモリアル スローン-ケタリング キャンサー センター Idタンパク質の小分子阻害剤
WO2021067820A1 (en) * 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
KR20220079606A (ko) * 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
BR112022005114A2 (pt) * 2019-10-04 2022-06-21 Seagen Inc Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
CN113274507B (zh) * 2020-02-20 2025-02-28 亚飞(上海)生物医药科技有限公司 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
US12029736B2 (en) 2020-02-25 2024-07-09 Mediboston Limited Camptothecin derivatives and conjugates thereof
KR20230023650A (ko) * 2020-05-13 2023-02-17 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법
WO2022078279A1 (zh) * 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
ES2963150T3 (es) 2020-10-27 2024-03-25 Elucida Oncology Inc Procedimientos para funcionalizar nanopartículas
KR20230133312A (ko) * 2021-01-15 2023-09-19 알.피.쉐러 테크놀러지즈 엘엘씨 캄프토테신 항체-약물 접합체 및 이의 사용 방법
CN116847844A (zh) * 2021-01-15 2023-10-03 R.P.谢勒技术有限责任公司 喜树碱抗体-药物缀合物及其使用方法
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN120093941A (zh) * 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
US12521444B2 (en) * 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
WO2022194257A1 (zh) * 2021-03-17 2022-09-22 江苏恒瑞医药股份有限公司 一种喜树碱衍生物的制备方法
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
CN115109118A (zh) * 2021-03-19 2022-09-27 博瑞生物医药(苏州)股份有限公司 一种固相合成ds-8201中间体的方法及ds-8201的制备方法
AR125473A1 (es) * 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
EP4349371A4 (en) * 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. DRUG CONJUGATE AND USE THEREOF
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
JP2024532768A (ja) * 2021-08-19 2024-09-10 ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド カンプトテシン誘導体、その薬物組成物およびその応用
CA3233254A1 (en) 2021-09-27 2023-03-30 Evopoint Biosciences Co., Ltd. Antibody, antibody-drug conjugate thereof and use thereof
PE20242114A1 (es) * 2021-11-09 2024-10-28 Tubulis Gmbh Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina
CN116199740A (zh) * 2021-12-01 2023-06-02 上海生物制品研究所有限责任公司 抗体药物偶联物及其用途
CN116354976B (zh) * 2021-12-27 2025-01-24 上海复旦张江生物医药股份有限公司 喜树碱衍生物的纯化方法
KR20240137076A (ko) 2022-01-25 2024-09-19 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 Her3에 대한 항체, 접합체 및 이의 용도
WO2023143208A1 (zh) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
KR20240150773A (ko) 2022-02-24 2024-10-16 에보포인트 바이오사이언시스 컴퍼니 리미티드 항체 및 약물 접합체 및 이의 용도
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
KR20240162575A (ko) 2022-03-25 2024-11-15 자임워크스 비씨 인코포레이티드 엽산 수용체 알파를 표적화하는 항체-약물 접합체 및 사용 방법
AU2023252914A1 (en) * 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN119255824A (zh) * 2022-04-14 2025-01-03 德比欧药物研究有限公司 具有改善的药代动力学和药物释放特性的配体-药物缀合物
KR20230149752A (ko) * 2022-04-20 2023-10-27 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
CN116966314A (zh) 2022-04-29 2023-10-31 成都百利多特生物药业有限责任公司 一种包含亲水性糖结构的配体-药物偶联物
WO2023214849A1 (ko) * 2022-05-04 2023-11-09 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신계 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체
US20230357763A1 (en) * 2022-05-06 2023-11-09 James E. Summerton Morpholinos with Increased Delivery Efficiency
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
AU2023278370A1 (en) * 2022-05-30 2025-01-09 Medilink Therapeutics (Suzhou) Co., Ltd. Preparation method for drug linker conjugate and intermediate thereof
CN118955614B (zh) * 2022-07-05 2025-12-30 上海药明合联生物技术有限公司 偶联连接子
KR20250049568A (ko) * 2022-07-15 2025-04-11 페온 테라퓨틱스 리미티드 Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도
KR20240035370A (ko) * 2022-09-08 2024-03-15 주식회사 피노바이오 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
WO2024073610A2 (en) * 2022-09-28 2024-04-04 Solve Therapeutics, Inc. Compositions and uses thereof
JP2025533758A (ja) 2022-10-14 2025-10-09 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド 抗体-薬物複合体並びにその調製方法及び使用
EP4605425A1 (en) * 2022-10-18 2025-08-27 Zymeworks BC Inc. Antibody-drug conjugates targeting glypican-3 and methods of use
WO2024114318A1 (zh) 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN116712561A (zh) 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 含n-亚甲基酰胺连接子的抗体-药物偶联物
KR20250145079A (ko) * 2023-02-09 2025-10-13 비원 메디슨즈 아이 게엠베하 자가 안정화 링커 접합체
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
WO2024210687A1 (ko) * 2023-04-06 2024-10-10 주식회사 피노바이오 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
CN120858098A (zh) * 2023-05-04 2025-10-28 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
IL324828A (en) * 2023-06-05 2026-01-01 Tripartite Therapeutics Inc Polar ligand-drug conjugate
CN122121899A (zh) * 2023-08-18 2026-05-29 康诺亚生物医药科技有限公司 五环类活性化合物及其偶联物和用途
WO2025048588A1 (ko) * 2023-08-31 2025-03-06 주식회사 피노바이오 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
CN121843944A (zh) * 2023-09-06 2026-04-10 劲方医药科技(上海)股份有限公司 大环化合物及其抗体-药物偶联物
IL327670A (en) 2023-10-11 2026-06-01 Antikor Biopharma Ltd Antibodies, conjugates, and uses thereof
CN120053678A (zh) * 2023-11-30 2025-05-30 上海医药集团股份有限公司 一种高喜树碱类抗体偶联药物、其制备方法及应用
CN122374343A (zh) 2023-11-30 2026-07-10 江苏康宁杰瑞生物制药有限公司 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途
CN122396493A (zh) * 2023-12-14 2026-07-14 上海盟科药业股份有限公司 喜树碱类似物的配体-药物偶联物及其用途
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025221986A1 (en) * 2024-04-18 2025-10-23 Cedars-Sinai Medical Center Targeted camptothecin derivatives for cancer treatment
WO2025223507A1 (zh) * 2024-04-25 2025-10-30 江苏康宁杰瑞生物制药有限公司 化合物及其偶联物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0540099T3 (da) 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
JPH06228141A (ja) * 1992-01-24 1994-08-16 Takeda Chem Ind Ltd 縮合複素環誘導体、その塩、その製造法および用途
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
SG88737A1 (en) * 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
US6629995B1 (en) * 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
KR101641345B1 (ko) * 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
US10195288B2 (en) * 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
JP7244987B2 (ja) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
TWI920652B (zh) * 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
KR20220079606A (ko) * 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
BR112022005114A2 (pt) * 2019-10-04 2022-06-21 Seagen Inc Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
KR20230023650A (ko) * 2020-05-13 2023-02-17 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법
CA3203777A1 (en) * 2020-12-03 2022-06-09 Seagen Inc. Modulating the immune response using anti-cd30 antibody-drug conjugates
JP2025501978A (ja) * 2022-01-05 2025-01-24 アジェンシス,インコーポレイテッド 191p4d12タンパク質に結合する抗体薬物コンジュゲート(adc)で筋層浸潤性尿路上皮癌または筋層浸潤性膀胱癌を治療するための方法
KR20250004952A (ko) * 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체

Also Published As

Publication number Publication date
AU2019247434A1 (en) 2020-10-08
CN111936169A (zh) 2020-11-13
JP2024042054A (ja) 2024-03-27
EP3773736A1 (en) 2021-02-17
CA3094313A1 (en) 2019-10-10
IL277748A (en) 2020-11-30
BR112020020466A2 (pt) 2021-01-12
EP3773736A4 (en) 2022-01-05
KR20210006362A (ko) 2021-01-18
SG11202009527PA (en) 2020-10-29
TW202010498A (zh) 2020-03-16
US20250135018A1 (en) 2025-05-01
US20190343828A1 (en) 2019-11-14
IL277748B1 (en) 2024-03-01
IL310391A (en) 2024-03-01
US20220193069A1 (en) 2022-06-23
MA52669A (fr) 2021-02-17
JP2021521111A (ja) 2021-08-26
AR114473A1 (es) 2020-09-09
WO2019195665A1 (en) 2019-10-10
EA202092410A1 (ru) 2021-02-09
JP7430643B2 (ja) 2024-02-13
IL277748B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MX2022003930A (es) Conjugados de péptido de camptotecina.
MX2024008677A (es) Conjugados de camptotecina.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020550805A1 (en) Exosomes for immuno-oncology and anti-inflammatory therapy
MX2022010457A (es) Derivados de camptotecina y conjugados de esta.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
CO2020013252A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
PH12021553000A1 (en) Multispecific proteins
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12018501589B1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12022550318A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
MX2018010491A (es) Proceso para la preparacion de un conjugado anticuerpo-rifamicina.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof